Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Objective To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy. M...
Gespeichert in:
| Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2017-02, Vol.69 (2), p.277-290 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 290 |
|---|---|
| container_issue | 2 |
| container_start_page | 277 |
| container_title | Arthritis & rheumatology (Hoboken, N.J.) |
| container_volume | 69 |
| creator | Fleischmann, Roy van Adelsberg, Janet Lin, Yong Castelar‐Pinheiro, Geraldo da Rocha Brzezicki, Jan Hrycaj, Pawel Graham, Neil M. H. van Hoogstraten, Hubert Bauer, Deborah Burmester, Gerd R. |
| description | Objective
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy.
Methods
Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co‐primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed.
Results
The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P |
| doi_str_mv | 10.1002/art.39944 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6207906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1841801579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5044-3cf9541b407532ed21463808dd81e6086bcbcec0938d0174be79d59382da0b2a3</originalsourceid><addsrcrecordid>eNqNks9uEzEQxlcIRKvSAy-ALHGBQ9qx1_vvgrRqKa1UCipBHC2vPUlc7dqp7S3KjUfgdfo6PAlO0laABMIXe8Y_f6MZf1n2nMIBBWCH0seDvGk4f5TtspyVk4JB8fj-TBu6k-2HcAVpNRWUUDzNdlhVl8Ap7Ga3n6Q3_TjIjkiryYWznXG9mxtFjk1AGfDHt-_vnTazlbFz0tpo_AITH9eEH-eBGEs-phBtDOSLiQvSqmhukFxuOWc0aX1ceBNN2BQ5s1Lj9ShjYjAsnQ1InE_p6Hr00iok0ZHpOKTkBSrvQnp4IlXcQAvTmXQKz7InM9kH3L_b97LPJ2-nR6eT8w_vzo7a84kqgPNJrmZNwWnHoSpyhppRXuY11FrXFEuoy051ChU0ea2BVrzDqtFFipiW0DGZ72VvtrrLsRtQq9Snl71YejNIvxJOGvH7jTULMXc3omRQNVAmgVd3At5djxiiGExQ2PfSohuDoHVZ57RiDP4D5bQGWlRNQl_-gV650ds0CcEoS79bcf5PKpVljNO8oYl6vaXWsw4eZw_dURBrk4lkMrExWWJf_DqOB_LeUgk43AJfTY-rvyuJ9nK6lfwJSl_fFg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1862241391</pqid></control><display><type>article</type><title>Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Fleischmann, Roy ; van Adelsberg, Janet ; Lin, Yong ; Castelar‐Pinheiro, Geraldo da Rocha ; Brzezicki, Jan ; Hrycaj, Pawel ; Graham, Neil M. H. ; van Hoogstraten, Hubert ; Bauer, Deborah ; Burmester, Gerd R.</creator><creatorcontrib>Fleischmann, Roy ; van Adelsberg, Janet ; Lin, Yong ; Castelar‐Pinheiro, Geraldo da Rocha ; Brzezicki, Jan ; Hrycaj, Pawel ; Graham, Neil M. H. ; van Hoogstraten, Hubert ; Bauer, Deborah ; Burmester, Gerd R.</creatorcontrib><description>Objective
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy.
Methods
Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co‐primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed.
Results
The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P < 0.0001). The mean change from baseline in the HAQ DI score at week 12 was significantly greater for sarilumab (least squares mean change: for 150 mg, −0.46 [P = 0.0007]; for 200 mg, −0.47 [P = 0.0004]) versus placebo (−0.26). Infections were the most frequently reported treatment‐emergent adverse events. Serious infections occurred in 1.1%, 0.6%, and 1.1% of patients receiving placebo, sarilumab 150 mg, and sarilumab 200 mg, respectively. Laboratory abnormalities included decreased absolute neutrophil count and increased transaminase levels in both sarilumab groups compared with placebo. In this study, reductions in the absolute neutrophil count were not associated with an increased incidence of infections or serious infections.
Conclusion
Sarilumab 150 mg and sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs improved the signs and symptoms of RA and physical function in patients with an inadequate response or intolerance to anti‐TNF agents. Safety data were consistent with interleukin‐6 receptor blockade and the known safety profile of sarilumab.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.39944</identifier><identifier>PMID: 27860410</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Abnormalities ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Rheumatoid - drug therapy ; Double-Blind Method ; Drugs ; Female ; Gangrene ; Humans ; Infections ; Interleukins ; Intolerance ; Male ; Middle Aged ; Monoclonal antibodies ; Necrosis ; Neutrophils ; Patients ; Pharmaceutical industry ; Prescription drugs ; Rheumatoid Arthritis ; Safety ; Severity of Illness Index ; Signs and symptoms ; Transaminase ; Tumor necrosis factor ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor necrosis factor-TNF ; Tumors</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2017-02, Vol.69 (2), p.277-290</ispartof><rights>2016 The Authors. published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology</rights><rights>2016, American College of Rheumatology.</rights><rights>2017, American College of Rheumatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5044-3cf9541b407532ed21463808dd81e6086bcbcec0938d0174be79d59382da0b2a3</citedby><cites>FETCH-LOGICAL-c5044-3cf9541b407532ed21463808dd81e6086bcbcec0938d0174be79d59382da0b2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.39944$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.39944$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27860410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fleischmann, Roy</creatorcontrib><creatorcontrib>van Adelsberg, Janet</creatorcontrib><creatorcontrib>Lin, Yong</creatorcontrib><creatorcontrib>Castelar‐Pinheiro, Geraldo da Rocha</creatorcontrib><creatorcontrib>Brzezicki, Jan</creatorcontrib><creatorcontrib>Hrycaj, Pawel</creatorcontrib><creatorcontrib>Graham, Neil M. H.</creatorcontrib><creatorcontrib>van Hoogstraten, Hubert</creatorcontrib><creatorcontrib>Bauer, Deborah</creatorcontrib><creatorcontrib>Burmester, Gerd R.</creatorcontrib><title>Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy.
Methods
Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co‐primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed.
Results
The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P < 0.0001). The mean change from baseline in the HAQ DI score at week 12 was significantly greater for sarilumab (least squares mean change: for 150 mg, −0.46 [P = 0.0007]; for 200 mg, −0.47 [P = 0.0004]) versus placebo (−0.26). Infections were the most frequently reported treatment‐emergent adverse events. Serious infections occurred in 1.1%, 0.6%, and 1.1% of patients receiving placebo, sarilumab 150 mg, and sarilumab 200 mg, respectively. Laboratory abnormalities included decreased absolute neutrophil count and increased transaminase levels in both sarilumab groups compared with placebo. In this study, reductions in the absolute neutrophil count were not associated with an increased incidence of infections or serious infections.
Conclusion
Sarilumab 150 mg and sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs improved the signs and symptoms of RA and physical function in patients with an inadequate response or intolerance to anti‐TNF agents. Safety data were consistent with interleukin‐6 receptor blockade and the known safety profile of sarilumab.</description><subject>Abnormalities</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Double-Blind Method</subject><subject>Drugs</subject><subject>Female</subject><subject>Gangrene</subject><subject>Humans</subject><subject>Infections</subject><subject>Interleukins</subject><subject>Intolerance</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Necrosis</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Prescription drugs</subject><subject>Rheumatoid Arthritis</subject><subject>Safety</subject><subject>Severity of Illness Index</subject><subject>Signs and symptoms</subject><subject>Transaminase</subject><subject>Tumor necrosis factor</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><issn>2326-5191</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqNks9uEzEQxlcIRKvSAy-ALHGBQ9qx1_vvgrRqKa1UCipBHC2vPUlc7dqp7S3KjUfgdfo6PAlO0laABMIXe8Y_f6MZf1n2nMIBBWCH0seDvGk4f5TtspyVk4JB8fj-TBu6k-2HcAVpNRWUUDzNdlhVl8Ap7Ga3n6Q3_TjIjkiryYWznXG9mxtFjk1AGfDHt-_vnTazlbFz0tpo_AITH9eEH-eBGEs-phBtDOSLiQvSqmhukFxuOWc0aX1ceBNN2BQ5s1Lj9ShjYjAsnQ1InE_p6Hr00iok0ZHpOKTkBSrvQnp4IlXcQAvTmXQKz7InM9kH3L_b97LPJ2-nR6eT8w_vzo7a84kqgPNJrmZNwWnHoSpyhppRXuY11FrXFEuoy051ChU0ea2BVrzDqtFFipiW0DGZ72VvtrrLsRtQq9Snl71YejNIvxJOGvH7jTULMXc3omRQNVAmgVd3At5djxiiGExQ2PfSohuDoHVZ57RiDP4D5bQGWlRNQl_-gV650ds0CcEoS79bcf5PKpVljNO8oYl6vaXWsw4eZw_dURBrk4lkMrExWWJf_DqOB_LeUgk43AJfTY-rvyuJ9nK6lfwJSl_fFg</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Fleischmann, Roy</creator><creator>van Adelsberg, Janet</creator><creator>Lin, Yong</creator><creator>Castelar‐Pinheiro, Geraldo da Rocha</creator><creator>Brzezicki, Jan</creator><creator>Hrycaj, Pawel</creator><creator>Graham, Neil M. H.</creator><creator>van Hoogstraten, Hubert</creator><creator>Bauer, Deborah</creator><creator>Burmester, Gerd R.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201702</creationdate><title>Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors</title><author>Fleischmann, Roy ; van Adelsberg, Janet ; Lin, Yong ; Castelar‐Pinheiro, Geraldo da Rocha ; Brzezicki, Jan ; Hrycaj, Pawel ; Graham, Neil M. H. ; van Hoogstraten, Hubert ; Bauer, Deborah ; Burmester, Gerd R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5044-3cf9541b407532ed21463808dd81e6086bcbcec0938d0174be79d59382da0b2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abnormalities</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Double-Blind Method</topic><topic>Drugs</topic><topic>Female</topic><topic>Gangrene</topic><topic>Humans</topic><topic>Infections</topic><topic>Interleukins</topic><topic>Intolerance</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Necrosis</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Prescription drugs</topic><topic>Rheumatoid Arthritis</topic><topic>Safety</topic><topic>Severity of Illness Index</topic><topic>Signs and symptoms</topic><topic>Transaminase</topic><topic>Tumor necrosis factor</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fleischmann, Roy</creatorcontrib><creatorcontrib>van Adelsberg, Janet</creatorcontrib><creatorcontrib>Lin, Yong</creatorcontrib><creatorcontrib>Castelar‐Pinheiro, Geraldo da Rocha</creatorcontrib><creatorcontrib>Brzezicki, Jan</creatorcontrib><creatorcontrib>Hrycaj, Pawel</creatorcontrib><creatorcontrib>Graham, Neil M. H.</creatorcontrib><creatorcontrib>van Hoogstraten, Hubert</creatorcontrib><creatorcontrib>Bauer, Deborah</creatorcontrib><creatorcontrib>Burmester, Gerd R.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fleischmann, Roy</au><au>van Adelsberg, Janet</au><au>Lin, Yong</au><au>Castelar‐Pinheiro, Geraldo da Rocha</au><au>Brzezicki, Jan</au><au>Hrycaj, Pawel</au><au>Graham, Neil M. H.</au><au>van Hoogstraten, Hubert</au><au>Bauer, Deborah</au><au>Burmester, Gerd R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2017-02</date><risdate>2017</risdate><volume>69</volume><issue>2</issue><spage>277</spage><epage>290</epage><pages>277-290</pages><issn>2326-5191</issn><eissn>2326-5205</eissn><abstract>Objective
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy.
Methods
Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co‐primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed.
Results
The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P < 0.0001). The mean change from baseline in the HAQ DI score at week 12 was significantly greater for sarilumab (least squares mean change: for 150 mg, −0.46 [P = 0.0007]; for 200 mg, −0.47 [P = 0.0004]) versus placebo (−0.26). Infections were the most frequently reported treatment‐emergent adverse events. Serious infections occurred in 1.1%, 0.6%, and 1.1% of patients receiving placebo, sarilumab 150 mg, and sarilumab 200 mg, respectively. Laboratory abnormalities included decreased absolute neutrophil count and increased transaminase levels in both sarilumab groups compared with placebo. In this study, reductions in the absolute neutrophil count were not associated with an increased incidence of infections or serious infections.
Conclusion
Sarilumab 150 mg and sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs improved the signs and symptoms of RA and physical function in patients with an inadequate response or intolerance to anti‐TNF agents. Safety data were consistent with interleukin‐6 receptor blockade and the known safety profile of sarilumab.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27860410</pmid><doi>10.1002/art.39944</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2326-5191 |
| ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2017-02, Vol.69 (2), p.277-290 |
| issn | 2326-5191 2326-5205 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6207906 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Abnormalities Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis Arthritis, Rheumatoid - drug therapy Double-Blind Method Drugs Female Gangrene Humans Infections Interleukins Intolerance Male Middle Aged Monoclonal antibodies Necrosis Neutrophils Patients Pharmaceutical industry Prescription drugs Rheumatoid Arthritis Safety Severity of Illness Index Signs and symptoms Transaminase Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF Tumors |
| title | Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A31%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sarilumab%20and%20Nonbiologic%20Disease%E2%80%90Modifying%20Antirheumatic%20Drugs%20in%20Patients%20With%20Active%20Rheumatoid%20Arthritis%20and%20Inadequate%20Response%20or%20Intolerance%20to%20Tumor%20Necrosis%20Factor%20Inhibitors&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Fleischmann,%20Roy&rft.date=2017-02&rft.volume=69&rft.issue=2&rft.spage=277&rft.epage=290&rft.pages=277-290&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.39944&rft_dat=%3Cproquest_pubme%3E1841801579%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1862241391&rft_id=info:pmid/27860410&rfr_iscdi=true |